Accelerating Rare disease Cures Program

The Accelerating Rare Disease Cures Program is a forecast opportunity issued by the Food and Drug Administration to support the Office of Neuroscience's efforts in advancing treatments for rare diseases. This initiative utilizes funding from the Budget Authority and the Prescription Drug User Fee Act to facilitate the development of critical medical cures. The project falls under NAICS code 541690 and is managed by the FDA. Interested parties can coordinate with the CDER Acquisition Liaison for program details, while the specific contracting officer is yet to be determined.